AzTrials
AzTrials

Acute Bipolar DepressionPhase 3QUALITYNCT00883493

Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression

A Phase 3 study testing Quetiapine fumarate XR and Lithium carbonate in people with Acute Bipolar Depression, run by AstraZeneca at 24 sites in 9 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to compare the efficacy of quetiapine fumarate monotherapy with quetiapine fumarate in combination with lithium in the treatment of a major depressive episode in patients with bipolar disorder. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Acute Bipolar Depression
What is being tested?
Quetiapine fumarate XR and Lithium carbonate
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
421 participants
Where
24 sitesin 9 countries
Study dates
Apr 2009to Mar 2011
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Outpatients that meet the diagnostic criteria for bipolar disorder I and bipolar disorder II with the most recent episode depressed
  • The total score of the scale that's used for the evaluation of depression (HAM-D) should be ≥20
  • The total score of the scale that' used for the evaluation of mania (YMRS) should be ≤12

Who cannot join

  • Patients with a current DSM-IV-TR Axis I disorder other than bipolar disorder within 6 months of enrollment. Patients who pose a current serious suicidal or homicidal risk
  • Use of drugs that induce or inhibit the hepatic metabolizing enzymes within 14 days before randomisation
  • Patients who are unable to discontinue all psychoactive medications, including antidepressants, antipsychotics, and mood stabilizers at least 7 days prior to randomisation and consistent with the pharmacokinetics of the drug

Trial locations and contacts

24 sites in 9 countries.

24 sites in 9 countries

Turkey (Türkiye)7 sites
  • Research Site

    Ankara, Turkey

  • Research Site

    Elâzığ, Turkey

  • Research Site

    Istanbul, Turkey

  • Research Site

    Izmir, Turkey

  • Research Site

    Kocaeli, Turkey

  • Research Site

    Malatya, Turkey

  • Research Site

    Manisa, Turkey

Other trials in Turkey (Türkiye)

Argentina4 sites
  • Research Site

    Caba

  • Research Site

    Godoy Cruz, Mendoza Province

  • Research Site

    La Plata, Buenos Aires

  • Research Site

    Mendoza, Mendoza Province

Other trials in Argentina

Mexico4 sites
  • Research Site

    Durango

  • Research Site

    Monterrey, Nuevo León

  • Research Site

    Monterrey

  • Research Site

    San Luis Potosí City, San Luis Potosí

Other trials in Mexico

Brazil3 sites
  • Research Site

    Aparecida de Goiânia, Goiás

  • Research Site

    Rio de Janeiro, Rio de Janeiro

  • Research Site

    São Paulo, São Paulo

Other trials in Brazil

Colombia2 sites
  • Research Site

    Bogota D.c, Cundinamarca

  • Research Site

    Medellín, Antioquia

Other trials in Colombia

Chile1 site
  • Research Site

    Santiago, Chile

Other trials in Chile

Guatemala1 site
  • Research Site

    Guatemala City, Ciudad de Guatemala

Other trials in Guatemala

Peru1 site
  • Research Site

    Lima, Lima Province

Other trials in Peru

Venezuela1 site
  • Research Site

    Caracas

Other trials in Venezuela

About this study

Official title: A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR TM) Tablets as Mono-Therapy or in Combination With Lithium in the Treatment of Patients With Acute Bipolar Depression

The purpose of this study is to compare the efficacy of quetiapine fumarate monotherapy with quetiapine fumarate in combination with lithium in the treatment of a major depressive episode in patients with bipolar disorder.

Being tested
Quetiapine fumarate XR, Lithium carbonate
Keywords
Acute bipolar depression, Lithium carbonate, quetiapine fumarate, MADRS

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Quetiapine fumarate XRDrug

    Also called SEROQUEL XR

    Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.

  • Lithium carbonateDrug

    Also called LITHURIL Tb in TURKEY, LITOCARB in PERU

    Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day

Study groups in NCT00883493
Study groupRoleWhat they receive
Quetiapin fumarate XRExperimentalQuetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
Receives: Drug: Quetiapine fumarate XR
Quetiapin fumarate XR+Lithium carbonateExperimentalQuetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56.
Receives: Drug: Quetiapine fumarate XR; Drug: Lithium carbonate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.

    The change of MADRS Total Score from baseline to the end of treatment was calculated by subtracting the MADRS Total Score assessed at week 8 from the baseline one (Baseline - 8 weeks).

    The MADRS is a 10-item scale that evaluates the core symptoms and cognitive features of clinical depression. Each MADRS item is rated on a 0 to 6 scale. The MADRS Total score ranges from 0 (min) to 60 (max). Higher MADRS scores indicate higher levels of depressive symptoms.

    Measured: Baseline, 8 weeks

Secondary outcomes (9)
  1. Response Rate for MADRS.

    Response rate defined as the percentage of patients with a ≥50% reduction from baseline in the MADRS total score to the final assessment at week 8.

    The MADRS is a 10-item scale that evaluates the core symptoms and cognitive features of clinical depression. Each MADRS item is rated on a 0 to 6 scale. The MADRS Total score ranges from 0 (min) to 60 (max). Higher MADRS scores indicate higher levels of depressive symptoms.

    Measured: baseline, week 8

  2. Hamilton Rating Scale for Depression (HAM-D) Total Score.

    The mean change of HAM-D Total Score from baseline to the end of treatment was calculated by subtracting the HAM-D Total Score assessed at week 8 from the baseline one (Baseline - week 8).

    HAM-D is a multiple choice questionnaire used to rate the severity of a patient's major depression. It consists of 17 different items with possible scores from 0 to 4 or 0 to 2 or 0 to 6 depending on the items. Sum the total of all seventeen items gives the HAM-D Total Score, which may range from 0 (min) to 53 (max). The higher the score, the more severe the depression.

    Measured: Baseline, 8 Weeks

  3. Change in Hamilton Rating Scale for Anxiety (HAM-A) Total Score

    The mean change in HAM-A total score from baseline to final assessment was calculated by subtracting the HAM-A Total score assessed at week 8 from the total score assessed at the baseline (baseline - week 8).

    The HAM-A is a 14-item scale that assesses anxiety symptoms of anxiety such as "anxious mood", "tension" or "fears". Each item is scored on a 5-point scale, ranging from 0=not present to 4=severe. Sum the scores from all 14 parameters gives the HAM-A Total Score which may range from 0 (min) to 56 (max).

    Measured: baseline, 8 weeks

  4. Change in the Clinical Global Impression Severity (CGI-S) Score.

    The reported mean change in the CGI-S score was calculated as baseline - week 8.

    CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment. A patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

    Measured: baseline, 8 weeks

  5. Change in Young Mania Rating Scale (YMRS) Total Score.

    The YMRS is a rating scale to assess manic symptoms. The scale has 11 items and is based upon patient's subjective report of his or hers clinical condition over the previous 48 hours.

    The mean change in YMRS Total score reported was calculated as baseline - week 8.

    The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).

    Measured: baseline, 8 weeks

  6. Change in the Pittsburgh Sleep Quality Index (PSQI)Total Score.

    The mean change in PSQI score from baseline to final assessment at week 8 was calculated as baseline - week 8.

    PSQI evaluates 7 areas of quality and pattern of sleep: sleep quality, duration getting to sleep, sleep duration, sleep adequacy, sleep disturbance, use of sleeping pill, and somnolence). Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.

    Measured: Baseline, 8 weeks

  7. Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Score.

    The mean change in (Q-LES-Q-Short Form) Total Score from baseline to week 8 was calculated by subtracting the 8 week value from baseline value (baseline - week 8).

    The Q-LES-Q-SF is a patient self assessment questionnaire consisting of 16 self-rated questions (1 being very poor - 5 very good); the first 14 will be incorporated into a total score. Higher scores indicate better quality of life.

    Measured: baseline, 8 weeks

  8. Change in the Sheehan Disability Scale (SDS) Total Score.

    The mean change in the SDS Total score from baseline to week 8 (baseline- week 8).

    Sheehan Disability Scale is a 5 item scale, with a visual analog scale evaluating work/school work, social life and family life ranging from 0 to a maximum score of 30. Each one of the 3 domains is rated from 0-10 (no impairment to most severe impairment) with evaluation of not at all (0), mild (1-3), moderate (4-6), marked (7-9) and extreme (10) disability. A total score will be calculated. A score of 30 indicates most severe impairment.

    Measured: baseline, 8 weeks

  9. Treatment Satisfaction Questionnaire (TSQ) Scores.

    The 14-item TAQ questionnaire evaluates the patient's overall level of satisfaction with the study medication, the effectiveness, side effects and convenience of the medication.

    Effectiveness, side effects, convenience and global satisfaction is rated on a scale of 0 being the worst and 100 being very effective, no side effects or very convenient or very satisfied. Overall satisfaction is rated over a score of 5 and 5 being the best overall satisfaction.

    Measured: baseline, 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Apr 2009 (estimated)
  2. Study startApr 2009
  3. Primary completionMar 2011
  4. Study completionMar 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
421 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00883493
Sponsor's protocol ID
D1443L00055
Acronym
QUALITY
Status last verified
Jul 2012
First submitted
16 Apr 2009
Last updated
11 Jul 2012
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Quetiapine fumarate XR and Lithium carbonate in people with Acute Bipolar Depression, run by AstraZeneca at 24 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 24 sites in Turkey (Türkiye), Argentina, Mexico, Brazil, Colombia and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Jun 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. (time frame: Baseline, 8 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in